AR040472A1 - Derivado de 2-(fenil)-2h-pirazol-3-carboxilico-n-4(tioxo-heterociclil)fenil-amida e imino-heterociclil derivados y compuestos relacionados, procedimiento, medicamentos, kit - Google Patents

Derivado de 2-(fenil)-2h-pirazol-3-carboxilico-n-4(tioxo-heterociclil)fenil-amida e imino-heterociclil derivados y compuestos relacionados, procedimiento, medicamentos, kit

Info

Publication number
AR040472A1
AR040472A1 AR20030102321A ARP030102321A AR040472A1 AR 040472 A1 AR040472 A1 AR 040472A1 AR 20030102321 A AR20030102321 A AR 20030102321A AR P030102321 A ARP030102321 A AR P030102321A AR 040472 A1 AR040472 A1 AR 040472A1
Authority
AR
Argentina
Prior art keywords
atoms
mono
hal
con
coor2
Prior art date
Application number
AR20030102321A
Other languages
English (en)
Inventor
Cezanne Bertram Dr
Mederski Werner Dr
Tsaklakidis Christos Dr
Gleitz Johannes Dr
Dorsch Dieter Dr
Barnes Christopher Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR040472A1 publication Critical patent/AR040472A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos son inhibidores del factor de coagulación Xa y pueden emplearse para la profilaxis y/o la terapia de enfermedades tromboembólicas y para el tratamiento de tumores. Reivindicación 1: Compuestos de la fórmula (1) donde: D está ausente o es una cadena de alquileno saturada, total o parcialmente no saturado de 3 a 4 miembros, en la cual 1 a 3 átomos de C pueden estar reemplazados por un átomo de N y/o 1 a 2 átomos de C pueden estar reemplazados por 1 a 2 átomos de O y/o 1 a 2 átomos de S, pero donde se reemplazan a lo sumo hasta 3 átomos de C y donde adicionalmente puede aparecer un mono, di o trisustitución de la cadena de alquileno y/o de un nitrógeno que se encuentra allí por Hal, A, -[C(R3)2]n-Ar, -[C(R3)2]n-Het, -[C(R3)2]n-cicloalquilo, OR2, N(R2)2, NO2, CN, COOR2, CON(R2)2, NR2COA, NR2SO2A, COR2, SO2NR2, y / o S(O)mA, y donde además un grupo CH2 de la cadena de alquileno puede estar reemplazado por un grupo C=O; M es un anillo de fenilo o un heterociclo aromático que puede contener 1-2 átomos de N, O y/o S; R1, R1' son en cada caso, independientemente entre sí, H, Hal, A, OR2, N(R2)2, NO2, CN, COOR2, CON(R2)2, C(=S)N(R2)2, -[C(R3)2]n-Ar, -[C(R3)2]n-Het o -[C(R3)2]n-cicloalquilo, -[C(R3)2]n-N(R3)2, CN, -C(=NH)-NH2 insustituido o monosustituido por C(=O)R3, COOR3, OR3, OCOR3, OCOOR3 o sustituido por un grupo de protección amino convencional, y de fórmula (2); R2 es H, A, -[C(R3)2]n-Ar, -[C(R3)2]n-Het, -[C(R3)2]n-cicloalquilo, -[C(R3)2]n-N(R3)2 o -[C(R3)2]n-OR3; R2' es H, A, -[C(R3)2]n-Ar', -[C(R3)2]n-Het', -[C(R3)2]n-cicloalquilo, -[C(R3)2]n-N(R3)2 o -[C(R3)2]n-OR3; R2'' es H, A, -[C(R3)2]n-Ar' o -[C(R3)2]n-cicloalquilo, -[C(R3)2]n-N(R3)2 o -[C(R3)2]n-OR3; R3 es H o A; W es un carbociclo o heterociclo mono o bicíclico saturado, no saturado o aromático con 1 a 4 átomos de N, O y/o S, que puede estar mono o disustituido por R2; X es CONR2, CONR2C(R3)2, -C(R3)2NR2 o -C(R3)2NR2C(R3)2, -C(R3)2O-, -C(R3)2OC(R3)2- o NR2CO; Y es alquileno, cicloalquileno, Het-diilo o Ar-diilo; T es un carbociclo o heterociclo mono o bicíclico saturado, no saturado o aromático con 1 a 4 átomos de N, O y/o S, que está mono o disustituido por =S, =NR2, =N-CN, =N-NO2, =NOR2, =NCOR2, =NCOOR2, =NOCOR2 y que además pueda estar mono, disustituido o trisustituido por Hal, A, -[C(R3)2]n-Ar, -[C(R3)2]n-Het -[C(R3)2]n-cicloalquilo, -OR3, N(R3)2, NO2, CN, COOR2, CON(R2)2, NR2COA, NR2CON(R2)2, NR2SO2A, COR2, SO2NR2 y/o S(O)mA; A es alquilo no ramificado o ramificado C1-10, donde uno o dos grupos CH2 pueden estar reemplazados por átomos de O o S y/o por grupos -CH=CH y/o también 1-7 átomos de H pueden estar reemplazados por F; Ar es fenilo, naftilo o bifenilo insustituido o mono, di o trisustituido por Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3SO2A, COR3, SO2N(R3)2, S(O)mA, -[C(R3)2]n-COOR2', u -O-[C(R3)2]o-COOR2'; Ar' es fenilo o bencilo insustituido o mono o disustituido por Hal; Het es un heterociclo mono o bicíclico saturado, no saturado o aromático con 1 a 4 átomos de N, O y/o S, que puede estar insustituido o mono, di o trisustituido por el oxígeno del carbonilo, =S, =N(R3)2, Hal, A, -[C(R3)2]n-Ar, -[C(R3)2]n-Het1, -[C(R3)2]n-cicloalquilo, -[C(R3)2]n-OR2', -[C(R3)2]n-N(R2')2, NO2, CN, -[C(R3)2]n-COOR2', -[C(R3)2]n-CON(R2')2, -[C(R3)2]n-NR2'COA, NR2'CON(R2')2, -[C(R3)2]n-NR2'SO2A, COR2', SO2NR2' y/o S(O)mA; Het1 es un heterociclo mono o bicíclico saturado, no saturado o aromático con 1 a 2 átomos de N, O y/o S, que puede estar insustituido o mono o disustituido por el oxígeno del carbonilo, =S, =N(R3)2, Hal, A, OR2'', N(R2'')2, NO2, CN, COOR2'', CON(R2'')2, NR2''COA, NR2''CON(R2'')2, NR2''SO2A, COR2'', SO2NR2'' y/o S(O)mA; Hal es F, Cl, Br o I; n es 0, 1 ó 2; m es 0, 1 ó 2; o es 1, 2 ó 3; así como los derivados, solvatos estereoisómeros de los mismos de uso farmacéutico, incluyendo las mezclas de los mismos en todas las proporciones.
AR20030102321A 2002-06-28 2003-06-27 Derivado de 2-(fenil)-2h-pirazol-3-carboxilico-n-4(tioxo-heterociclil)fenil-amida e imino-heterociclil derivados y compuestos relacionados, procedimiento, medicamentos, kit AR040472A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10229070A DE10229070A1 (de) 2002-06-28 2002-06-28 Phenylderivate 5

Publications (1)

Publication Number Publication Date
AR040472A1 true AR040472A1 (es) 2005-04-06

Family

ID=29723536

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102321A AR040472A1 (es) 2002-06-28 2003-06-27 Derivado de 2-(fenil)-2h-pirazol-3-carboxilico-n-4(tioxo-heterociclil)fenil-amida e imino-heterociclil derivados y compuestos relacionados, procedimiento, medicamentos, kit

Country Status (8)

Country Link
US (1) US20050203127A1 (es)
EP (2) EP1517685A1 (es)
JP (1) JP2005535630A (es)
AR (1) AR040472A1 (es)
AU (1) AU2003238475A1 (es)
CA (1) CA2491271A1 (es)
DE (1) DE10229070A1 (es)
WO (1) WO2004002477A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001269531A1 (en) * 2000-07-17 2002-01-30 Takeda Chemical Industries Ltd. Sulfone derivatives, process for their production and use thereof
EP1564213A4 (en) * 2002-11-22 2009-05-27 Takeda Pharmaceutical IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
DE102004051277A1 (de) * 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
CN101087609B (zh) 2004-10-26 2012-11-14 詹森药业有限公司 因子Xa化合物
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
DE102005045115A1 (de) * 2005-09-21 2007-04-05 Siemens Ag Verfahren und Vorrichtung zum Betrieb eines Kommunikationsendgeräts
US8338367B2 (en) 2008-10-15 2012-12-25 Boehringer Ingelheim International Gmbh Fused heteroaryl diamide compounds useful as MMP-13 inhibitors
JP5529876B2 (ja) 2008-10-17 2014-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−１３阻害剤として有用なヘテロアリール置換インドール化合物
RU2017144535A (ru) 2010-03-30 2019-02-18 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
AU2014238478B2 (en) 2013-03-15 2018-07-19 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
AU2014232308B2 (en) 2013-03-15 2017-11-09 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
ES2773303T3 (es) 2013-10-14 2020-07-10 Eisai R&D Man Co Ltd Compuestos de quinolina sustituidos selectivamente
US9663486B2 (en) 2013-10-14 2017-05-30 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
CN113307772B (zh) 2014-03-07 2024-06-28 拜奥克里斯特制药公司 人类血浆激肽释放酶抑制剂
AU2015317522A1 (en) 2014-09-17 2017-03-23 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
ES2931460T3 (es) 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK86699A3 (en) * 1996-12-23 2000-11-07 Du Pont Pharm Co Nitrogen containing heteroaromatics as factor xa inhibitors
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
IL133526A0 (en) * 1997-06-19 2001-04-30 Du Pont Pharm Co Inhibitors of factor xa with a neutral p1 specificity group
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group

Also Published As

Publication number Publication date
DE10229070A1 (de) 2004-01-15
US20050203127A1 (en) 2005-09-15
EP1679073A1 (de) 2006-07-12
WO2004002477A8 (de) 2004-04-15
WO2004002477A1 (de) 2004-01-08
EP1517685A1 (de) 2005-03-30
JP2005535630A (ja) 2005-11-24
CA2491271A1 (en) 2004-01-08
AU2003238475A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
AR040472A1 (es) Derivado de 2-(fenil)-2h-pirazol-3-carboxilico-n-4(tioxo-heterociclil)fenil-amida e imino-heterociclil derivados y compuestos relacionados, procedimiento, medicamentos, kit
AR041024A1 (es) Derivados de benzimidazol como inhibidores del factor de coagulacion xa
RU2345993C2 (ru) ЛАКТАМСОДЕРЖАЩЕЕ СОЕДИНЕНИЕ И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
AR049502A1 (es) Derivados de carbonilo heterociclicos
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
ECSP024364A (es) Antagonistas receptores de adenosina a2a
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
AR037754A1 (es) Herbicidas
DE60212836D1 (de) Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
AR065937A2 (es) Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa
EA201890903A9 (ru) Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
ATE349463T1 (de) Verbrückte bizyklische serinproteaseinhibitoren
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
AR045938A1 (es) Peptidos macrociclicos activos contra el virus de la hepatitis c
AR063099A1 (es) Compuestos y composiciones como inhibidores de la proteina quinasa
UY29246A1 (es) Nuevos compuestos
AR032136A1 (es) Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
PE20241129A1 (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren

Legal Events

Date Code Title Description
FA Abandonment or withdrawal